Oppenheimer & Co’s TG Therapeutics TGTX Stock Holding History

Oppenheimer & Co’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.43M	Buy	+26,014	New	+$1.06M	0.02%	775
2024 Q4	–	Sell	-32,470	Closed	-$759K	–	1644
2024 Q3	$759K	Buy	+32,470	New	+$709K	0.01%	887
2021 Q3	–	Sell	-5,400	Closed	-$209K	–	1572
2021 Q2	$209K	Sell	5,400 -5,700	-51%	-$224K	﹤0.01%	1406
2021 Q1	$535K	Buy	+11,100	New	+$533K	0.01%	938

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Oppenheimer & Co's TGTX Position: Q2 2026 in Review

Oppenheimer & Co opened a new position in TG Therapeutics (TGTX) in Q2 2026: 26,014 shares worth $1.43M. The stake represents 0.02% of the portfolio and ranks #775 among its holdings. This is a return to the name: Oppenheimer & Co previously reported a position in TGTX as recently as Q3 2024.

Oppenheimer & Co first reported a position in TGTX in Q1 2021 and has held it in 4 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Oppenheimer & Co held 26,014 shares of TG Therapeutics worth $1.43M as of Q2 2026.
TG Therapeutics was a new Oppenheimer & Co position in Q2 2026.
TG Therapeutics made up 0.02% of Oppenheimer & Co's portfolio in Q2 2026, its #775 holding.
Oppenheimer & Co first reported a position in TG Therapeutics in Q1 2021 and has held it in 4 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.